

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – March 6, 2007

NOTICE OF STATUS CHANGE

This study will re-open for the accrual of 1 additional patient at dose level 1 effective Tuesday, March 6, 2007.

Please retain this notice with the protocol.